eHealth Valuation
Is EHTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EHTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate EHTH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate EHTH's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EHTH?
Key metric: As EHTH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is EHTH's PS Ratio? | |
|---|---|
| PS Ratio | 0.3x |
| Sales | US$464.89m |
| Market Cap | US$152.02m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | -25.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does EHTH's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1x | ||
AIFU AIX | 0.2x | 15.8% | US$72.0m |
CCG Cheche Group | 0.1x | 5.6% | US$70.2m |
GOCO GoHealth | 0.2x | 8.0% | US$258.8m |
ZBAO Zhibao Technology | 3.3x | 36.7% | US$88.9m |
EHTH eHealth | 0.3x | 8.3% | US$152.0m |
Price-To-Sales vs Peers: EHTH is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1x).
Price to Sales Ratio vs Industry
How does EHTH's PS Ratio compare vs other companies in the US Insurance Industry?
Price-To-Sales vs Industry: EHTH is good value based on its Price-To-Sales Ratio (0.3x) compared to the US Insurance industry average (1.1x).
Price to Sales Ratio vs Fair Ratio
What is EHTH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.3x |
| Fair PS Ratio | 1.9x |
Price-To-Sales vs Fair Ratio: EHTH is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (1.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$4.95 | US$7.67 +54.9% | 53.6% | US$13.00 | US$3.00 | n/a | 3 |
| Nov ’25 | US$4.86 | US$6.67 +37.2% | 69.6% | US$13.00 | US$2.00 | n/a | 3 |
| Oct ’25 | US$4.14 | US$6.67 +61.0% | 69.6% | US$13.00 | US$2.00 | n/a | 3 |
| Sep ’25 | US$4.05 | US$6.67 +64.6% | 69.6% | US$13.00 | US$2.00 | n/a | 3 |
| Aug ’25 | US$4.99 | US$8.00 +60.3% | 44.5% | US$13.00 | US$5.00 | n/a | 3 |
| Jul ’25 | US$4.60 | US$8.00 +73.9% | 44.5% | US$13.00 | US$5.00 | n/a | 3 |
| Jun ’25 | US$5.92 | US$8.00 +35.1% | 44.5% | US$13.00 | US$5.00 | n/a | 3 |
| May ’25 | US$4.46 | US$8.33 +87.1% | 40.8% | US$13.00 | US$5.00 | n/a | 3 |
| Apr ’25 | US$5.76 | US$8.36 +45.1% | 35.2% | US$13.00 | US$5.00 | n/a | 4 |
| Mar ’25 | US$6.56 | US$8.36 +27.4% | 35.2% | US$13.00 | US$5.00 | n/a | 4 |
| Feb ’25 | US$7.25 | US$9.11 +25.6% | 25.3% | US$13.00 | US$7.00 | n/a | 4 |
| Jan ’25 | US$8.72 | US$10.11 +15.9% | 20.0% | US$13.00 | US$8.00 | n/a | 4 |
| Dec ’24 | US$8.05 | US$10.11 +25.6% | 20.0% | US$13.00 | US$8.00 | n/a | 4 |
| Nov ’24 | US$8.52 | US$10.61 +24.5% | 15.6% | US$13.00 | US$8.43 | US$4.86 | 4 |
| Oct ’24 | US$7.40 | US$11.33 +53.2% | 11.0% | US$13.00 | US$10.00 | US$4.14 | 3 |
| Sep ’24 | US$7.61 | US$10.80 +41.9% | 10.8% | US$13.00 | US$10.00 | US$4.05 | 5 |
| Aug ’24 | US$8.32 | US$9.60 +15.4% | 27.6% | US$13.00 | US$5.00 | US$4.99 | 5 |
| Jul ’24 | US$8.04 | US$9.60 +19.4% | 27.6% | US$13.00 | US$5.00 | US$4.60 | 5 |
| Jun ’24 | US$6.87 | US$9.60 +39.7% | 27.6% | US$13.00 | US$5.00 | US$5.92 | 5 |
| May ’24 | US$6.46 | US$9.20 +42.4% | 31.0% | US$13.00 | US$5.00 | US$4.46 | 5 |
| Apr ’24 | US$9.36 | US$9.80 +4.7% | 26.9% | US$13.00 | US$5.00 | US$5.76 | 5 |
| Mar ’24 | US$8.07 | US$7.10 -12.0% | 63.4% | US$16.00 | US$4.00 | US$6.56 | 5 |
| Feb ’24 | US$8.39 | US$6.90 -17.8% | 66.8% | US$16.00 | US$4.00 | US$7.25 | 5 |
| Jan ’24 | US$4.84 | US$6.90 +42.6% | 66.8% | US$16.00 | US$4.00 | US$8.72 | 5 |
| Dec ’23 | US$4.42 | US$6.90 +56.1% | 66.8% | US$16.00 | US$4.00 | US$8.05 | 5 |
| Nov ’23 | US$2.68 | US$10.50 +291.8% | 24.4% | US$16.00 | US$8.00 | US$8.52 | 6 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Sagicor Financial
CA$874.2m
Provides insurance products and related financial services in Jamaica, Barbados, Trinidad, Tobago, other Caribbean region, and the United States.
SGCF.F
CA$4.46
7D
0%
1Y
-0.5%
Fairfax Financial Holdings
CA$42.8b
Through its subsidiaries, provides property and casualty insurance and reinsurance, and investment management services in the United States, Canada, Asia, and internationally.
FRFH.F
CA$1,401.10
7D
2.2%
1Y
54.5%
Aviva
UK£12.8b
Provides various insurance, retirement, investment, and savings products in the United Kingdom, Ireland, Canada, and internationally.
AVVI.Y
UK£12.41
7D
2.6%
1Y
16.3%